MELBOURNE, Australia — Telix Pharmaceuticals Limited (ASX: TLX) today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET). The granted Fast Track designation is for the characterisation of progressive or recurrent glioma using...
Latest News
MELBOURNE, Australia — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 – 13 March 2023. Further data from...
ANDOVER, Mass. — TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with...
SOUTH SAN FRANCISCO, Calif. – Tenaya Therapeutics, a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the hires of Leone Patterson, MBA, as Chief Financial and Business Officer and Matthew Pollman, MD, MS, as Senior Vice...
São Paulo, Brazil. In recent years, physicians and scientists in parts of Brazil where visceral leishmaniasis (VL) is endemic have seen rising numbers of cases of co-infection by Leishmania infantum and Crithidia, also a protozoan but hitherto believed to be a mosquito parasite that cannot infect humans or other mammals. Accurate diagnosis...
Tallinn, Estonia – Surprisingly high fraction of infertile men presenting congenital testicular maldescent, cryptorchidism, were revealed as undiagnosed cases of congenital RASopathy syndromes, as stated in a recent publication by researchers from the University of Tartu and the Andrology Clinic of Tartu University Hospital. Approximately 2-4% of male newborns are...
GRAND RAPIDS, Mich. – Tetra Therapeutics, a wholly owned subsidiary of Shionogi & Co. Ltd., today announced positive topline results from its Phase 2 exploratory study in adult patients with Fragile X Syndrome (FXS). The study evaluated its lead candidate, BPN14770, a first-in-class phosphodiesterase‐4D (PDE4D) allosteric inhibitor. In this single-center,...
GRAND RAPIDS, Mich. – Tetra Therapeutics, a clinical stage biopharmaceutical company focused on the development of compounds for the treatment of brain disorders associated with cognitive and memory deficits, notably BPN14770, a selective inhibitor of phosphodiesterase‐4D (PDE4D), announced changes to its executive team as the company marks one year since...
TEL AVIV & WENDELSHEIM, Germany – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with...
San Antonio, Texas – In findings that have implications for potential new HIV therapies, researchers from Texas Biomedical Research Institute (Texas Biomed) used genetic sequencing techniques on the nonhuman primate version of the virus to identify that lymph nodes in the abdomen are the leading source of rebound infection after...